PROTAC Technology: Opportunities and Challenges

PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.

PROTACs have opened a new chapter for the development of new drugs and novel chemical knockdown tools and brought unprecedented opportunities to the industry and academia, which are mainly reflected in the following aspects:Overcoming drug resistance of cancer;Eliminating both the enzymatic and nonenzymatic functions of kinase;Degrade the “undruggable” protein target;Fast and reversible chemical knockdown strategy in vivo.

TargetMol offers small molecules for the development of new drugs:
CompoundCASTarget
ARV-8251818885-28-7BRD4
dBET11799711-21-9BRD4
ARV-7711949837-12-0BET
dBET61950634-92-0BET
MZ11797406-69-9BRD4
Gefitinib-based PROTAC 32230821-27-7EGFR
PROTAC CDK9 Degrader-12118356-96-8CDK9
BRD4 degrader AT12098836-45-2BRD4
dBET571883863-52-2BRD4
A18742064292-12-0BRD4
BSJ-03-123T5395CDK6
We believe that with the help of our fast and efficient global supply chain, professional and rigorous procurement process, and timely dynamic products, you will save more time for less cost and lead in both biology research and early drug discovery and screening. For more informations, you can visit www.targetmol.com Our email address: sales@targetmol.com(US Customer) or info@targetmol.com(International Customer).

Leave a Reply

Your email address will not be published. Required fields are marked *